RxDoctor Payments Data

Irving Restituyo, MD

Geriatric Medicine · New Bedford, MANPI 1093876906

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $7,370 of the $8,968 with a category attached, or 82.2%. Johnson & Johnson accounts for 97.6% of it on its own, with 3 other manufacturers making up the rest. Among geriatric medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,968in general payments, 2019–2025

Across 31 payments — averaging $289.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$9K
  • Sunovion Pharmaceuticals Inc.$124
  • Merz North America, Inc.$79
  • Indivior Inc.$15

What the payments were for

  • Speaking & faculty fees$7,37082%
  • Travel & lodging$1,13313%
  • Food & beverage$4655%

General payments by program year

19
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,968 in reported general payments places this provider in the 95th percentile of 156 geriatric medicine providers in Massachusetts.

See all geriatric medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$355,911
Medicare patients
1,142
Services billed
3,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban2,865$805,201
NuplazidPimavanserin Tartrate241$455,844
XareltoRivaroxaban921$232,028
TrulicityDulaglutide279$208,134
JanuviaSitagliptin Phosphate558$152,475
Invega SustennaPaliperidone Palmitate49$129,210
JardianceEmpagliflozin395$121,485
XifaxanRifaximin105$111,007
AustedoDeutetrabenazine18$96,716
RexultiBrexpiprazole123$77,203
Divalproex Sodium967$66,165
MyrbetriqMirabegron283$63,952
OtezlaApremilast26$60,131
OzempicSemaglutide53$53,063
FarxigaDapagliflozin Propanediol168$50,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Invega Sustenna, Procrit$8,750$388,8661,006 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 156 geriatric medicine providers in Massachusetts.

Other geriatric medicine in New Bedford

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →